drugset / Trial / NCT02262650

Relative Bioavailability of Telmisartan and SR26334 After Co-administration Compared to the Bioavailability of Telmisartan and SR26334 After Administration of Telmisartan and Clopidogrel Alone in Healthy Male and Female Subjects

NCT02262650

Phase 1 Completed 24 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Study to investigate the relative bioavailability of concomitant administration of clopidogrel and telmisartan (Test 1) relative to the bioavailability of SR26334 alone (Reference 1), and relative to the bioavailability of telmisartan alone (Reference 2). And to investigate the bioavailability of SR26334 following administration of clopidogrel 30 minutes after intake of telmisartan (Test 2) relative to the bioavailability of SR26334 alone (Reference 1), and relative to the bioavailability of telmisartan alone (Reference 2)

Timeline

Start
2004-04
Primary completion
2004-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Clopidogrel Small molecule 75 mg Oral
Subject Telmisartan Other / unclassified 80 mg Oral

Indications

No indication recorded.